Hearing Rehabilitation with the Closed-Skin Bone-Anchored implant Sophon o Alpha1: Results of a Prospective Study in 15 Children with Ear Atresia

Presented at the Politzer Society Meeting, November 16, 2013 in Antalya, Turkey

Summary of a Clinical Study Françoise Denoyelle, principal investigator

Authors	 Françoise Denoyelle[*] Nicolas LeBoulanger[*] Cyrille Coudert[*] C 	latalie Loundon' (incent Couloigner')livia Mazzaschi'	 Eric Vicaut[*] Natacha Tessier[*] Noel Garabedian[*] 		
	 Department of Pediatric Otolaryngology, Necker Childrens Hospital, APHP, University of Paris, Paris, France Audionova Audiometry Center - 75015 Paris, France Department of Clinical Research, Centre D'évaluation Des Dispositifs Médicaux, APHP, University of Paris, Paris, France 				
Patients	 15 patients underwent Sophono implantation – 12 before and 3 during auricle reconstruction Patient ages ranged from 5 years, 1 month to 12 years, 11 months; median age was 8 years Follow-up period was between 12 and 30 months 				
Evaluations	At 6 and 12 months after implantation (M12):	Tonal and vocal air-conduction audiometry in free field with masking of the contralateral ear, with and without Alpha 1			
		Speech-in-noise tests with and without Alpha1, noise at 65 dB, in real-life conditions			
	At 12 months and until 33 months after implantation (M12):	Skin evaluation at the end of follow-up			
Other Parameters	First use of the external device after the procedure		1 month		
	Sophono processor type		Alpha 1		
	Most common cause of hearing loss		High-grade ear atresia		



Timeline	 All 15 patients were enrolled and followed between October 2010 and November 2013 				
Clinical Results	(Note: Average air-bone gap was 57.4 dB) Pure-Tone Average	Pre-Op 69.1 dB	Post-Op 28.4 dB	Improvement 43.0 dB	
	Speech-In-Noise Ratio	71.7 dB	38.2 dB	33.5 dB	
	Alpha 1 vs. BAHA [®] testing with the BAHA used on a softband (Note: Performance for the Alpha 1 was the same on the softband and on the Sophono implant.)	PTA improvement: The Alpha 1 performed 5 dB (on average) better than the BAHA on softband. The gain with Sophono processor falls between the gain on BAHA on softband and BAHA percutaneous. Sophono is a "good indication in children" because it is easy for the child to put the processor in place. (Note: BAHA suffers from problems of granuloma/trauma and difficulties in thin cortical bones.)			
Conclusion	 The Alpha 1 implant in children with (aided PTA / improvement of speed up of 20 months. 	congenital aural ch-in-noise), and	atresia showed satisfying au I good cutaneous tolerance	uditory results with a mean follow-	

Rx only. Refer to product instruction manual/package insert for instructions, warnings, precautions and contraindications.

For further information, please call Medtronic ENT at 800.874.5797 or consult Medtronic's website at **www.medtronicent.com**.



Now owned by

Medtronic

Sophono Inc.

5744 Central Avenue Suite 100 Boulder, CO 80301

International Telephone Numbers

Adriatic Region 385-1-488-1120 Argentina 54-11-4898-5700 Australia 1-800-668-670 Baltic Region 37-1-67560226 Belgium 32-2456-09-09 Brazil 55-11-2182-9200 Canada 1-800-217-1617 Chile 56-2-2655-5110 China 86-21-20325888 Colombia 57-1-742-7300 Czech Republic 420-2-9657-9580 France 33-470-679-800 Germany 49-2159-8149-209 Greece 30-210-67-79-099 Hong Kong 852-2919-1300 Hungary 36-188-90600 India 91-22-26836733

Israel 972-9-972-4400 Italy 39-02-24137-324 Japan 81-3-6430-2017 Korea 82-2-3404-3600 Lebanon 961-1-370-670 Luxembourg 32-2456-09-09 Malaysia 60-37-953-4800 Mexico 52-55-11-02-90-30 Netherlands 31-45-566-8800 Poland 48-22-4656900 Russian Fed. 7-495-580-73-77 Singapore 65-6776-6255 South Africa 27-11-466-1820 Spain 34-91-625-05-40 Taiwan 886-2-2183-6000 Thailand 662-232-7400 UK 44-1923-205-166

Sophono[™] and *The Leader in Magnetic Bone Conduction Hearing* are registered trademarks of Medtronic, Inc. © 2016, Medtronic, Inc. S0584-02 Rev B UC201700045 EN 07.2016